Energy News / Shareholders Foundation, Inc.

NYSE:MNK Shareholder Notice: Lawsuit Alleges Misleading Statements by Mallinckrodt Plc

Via: ReleaseWire

Updated 11:30 AM CDT, Mon, August 12,2019

A lawsuit was filed on behalf of investors in Mallinckrodt plc (NYSE: MNK) shares over alleged securities laws violations.

San Diego, CA -- (SBWIRE) -- 08/12/2019 -- An investor, who purchased shares of Mallinckrodt plc (NYSE: MNK), filed a lawsuit over alleged violations of Federal Securities Laws by Mallinckrodt plc in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Mallinckrodt plc (NYSE: MNK) have certain options and for certain investors are short and strict deadlines running. Deadline: September 24, 2019. NYSE: MNK investors should contact the Shareholders Foundation at or call +1(858) 779 - 1554.

UK based Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. Among other products, Mallinckrodt's portfolio includes H.P. Acthar Gel ("Acthar"), an injectable drug for various indications, such as rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others. Between February 28, 2018 and July 16, 2019, Acthar was in a Phase 2B study designed to assess its efficacy and safety as an investigational treatment for amyotrophic lateral sclerosis ("ALS").

On May 1, 2019, the Wall Street Journal published an article claiming that Questcor, acquired by Mallinckrodt in 2014, "defrauded government health-care plans by illegally marketing H.P. Acthar Gel." The Company purportedly resorted to bribing doctors and their staff members. To market this expensive drug, the Company allegedly offered everything from Starbucks gift cards to free Las Vegas trips, lavish dinners, sponsored happy hours and karaoke excursions.

Then, on July 16, 2019, post-market, Mallinckrodt announced that the Company was permanently discontinuing the PENNANT Trial, assessing Acthar's safety and efficacy as an ALS treatment. Mallinckrodt stated that it decided "to halt the trial after careful consideration of a recent recommendation by the study's independent Data and Safety Monitoring Board" ("DSMB"), which "was based on the specific concern for pneumonia, which occurred at a higher rate in the ALS patients receiving Acthar Gel compared to those on placebo" and that "the board also mentioned other adverse events specific to this patient population."

The plaintiff claims that between February 28, 2018 and July 16, 2019, the Defendants made false and/or misleading statements and/or failed to disclose that Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS, that accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Mallinckrodt plc (NYSE: MNK) have certain options and should contact the Shareholders Foundation.

Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:

Media Relations Contact
Michael Daniels
Email: Click to Email Michael Daniels